AU2018370164B2 — Use of carbamate compound for reducing or treating developmental disorders including fragile X syndrome, Angelman syndrome or Rett syndrome
Assigned to SK Biopharmaceuticals Co Ltd · Expires 2024-08-15 · 2y expired
What this patent protects
The present invention relates to a use of a carbamate compound represented by chemical formula 1, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof for reducing or treating developmental disorders including fragile X syndrome, Angelman syndrome or Rett syndrom…
USPTO Abstract
The present invention relates to a use of a carbamate compound represented by chemical formula 1, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof for reducing or treating developmental disorders including fragile X syndrome, Angelman syndrome or Rett syndrome.
Drugs covered by this patent
- Xcopri (CENOBAMATE) · Sk Life
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.